Halozyme’s HyperCon Timelines, $1B Royalty Assumptions Don’t Align in Q2 2026 Earnings Call

<<>>

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $481M, up 48% YOY
• EPS: $2.28 non-GAAP diluted EPS, up 49% YOY from $1.54
• Operating Margin: Adjusted EBITDA margin of more than 65%

Guidance:

• Raised total revenue guidance for 2026 to $1.835B-$1.91B (31%-37% YOY growth).
• Royalty revenue expected to be $1.22B-$1.245B (41%-43% YOY growth).
• Adjusted EBITDA expected between $1.225B-$1.28B.
• Non-GAAP diluted EPS expected $8.65-$9.00.

Business Commentary:

Revenue Growth and Royalty Expansion:

• Halozyme reported a total revenue increase of 48% year-over-year to $481 million for the second quarter, driven by a 50% year-over-year growth in royalty revenue to $308 million.
• The growth was attributed to enhanced royalty revenue from newer launch products and the continued success of established products.

New Partnerships and Collaboration Milestones:

• The company signed four new collaboration and licensing agreements in the second quarter, with a fifth agreement signed in July, marking the highest pace of new deals in its history.
• These agreements included three for the Enhance platform and two for the HyperCon platform, expanding into new modalities like ADCs and nucleic acids.

Development Pipeline and Future Launches:

• Halozyme advanced its pipeline with two new Phase 1 study starts, aiming to have up to 13 Enhanced development programs by year-end 2026.
• The goal is to create a substantial portfolio of future royalty opportunities, extending into the next decade, with potential approvals beginning in the 2029 plus timeframe.

Financial Performance and Margin Strength:

• The company reported an adjusted EBITDA of $329 million, with an adjusted EBITDA margin of more than 65%, and non-GAAP earnings per share of $2.28.
• This performance highlights the strength of its diversified royalty portfolio and the operating leverage inherent in its business model.

Share Repurchase and Capital Allocation:

• Halozyme executed $332.8 million worth of share repurchases in the second quarter, utilizing its strong financial position to return excess capital to shareholders.
• The repurchases were part of a disciplined capital allocation strategy aimed at supporting shareholder value amid the company's growth trajectory.

Sentiment Analysis:

Overall Tone: Positive

• CEO described results from 'an exceptionally strong second quarter' with 'record total royalty revenue growth of 50% year-over-year.' Management raised full-year 2026 guidance and expressed confidence in the 2026-2028 financial guidance and beyond, stating 'our record second quarter results reinforce our confidence in both the strength of our business today and in the opportunities ahead.'

Q&A:

• Question from Sean Lehman (Morgan Stanley) via Natasha: The raised royalty guide implies an acceleration in the back half; is it driven by newer launches or established products?
  Response: The sequential growth in royalties is expected to continue in the second half, primarily driven by new product launches like Rybervant SubQ.

• Question from Michael DeFiore (Evercore ISI): How will target exclusivity patterns evolve through 2029, and does it open up new targets?
  Response: A mix of exclusive and non-exclusive deals is expected; companies are comfortable with non-exclusive licenses, allowing for creative licensing (e.g., exclusivity to a target or molecule).

• Question from Brendan Smith (TD Cowan): What is the timing for subsequent HyperCon assets and how many contribute to the $1B+ royalty target by mid-2030s?
  Response: Additional HyperCon study starts could occur in 2H 2027; the $1B+ royalty by mid-2030s assumes 5-7 launches, potentially from both signed agreements and future deals.

• Question from Mitchell Kapoor (HC Wainwright) via Ahmed: How should we think about HyperCon manufacturing revenue beyond royalties and investment, and attrition in the 13 development programs?
  Response: HyperCon manufacturing is an exciting investment to accelerate growth; details not finalized. The 13 development programs by end-2026 are a mix of antibodies and new mechanisms, with launches expected between 2029-2033, not all in 2029.

• Question from Dave Reisinger (Lee Rink Partners): Update on Merck litigation, view on AltheaGen as a competitor, and the acquisition landscape.
  Response: Merck litigation is active outside the U.S. with preliminary injunctions; U.S. case clarity expected later this year. AltheaGen is not a direct competitor as companies prefer Halozyme's proven track record. M&A remains a capital allocation priority but is unlikely in 2026, focusing on organic growth.

Contradiction Point 1

Timing for Subsequent HyperCon Study Starts

Conflicting timelines for when additional HyperCon studies will begin.

Brendan Smith (TD Cowan) - Brendan Smith (TD Cowan)

2026Q2: Additional HyperCon study starts could occur in the second half of 2027, as partners advance multiple targets. - Dr. Helen Torley(CEO)

What is the timing of subsequent HyperCon assets beyond the initial two, and how many assets are assumed in the $1 billion incremental HyperCon royalty target by 2035, based on current or future partnerships? - Brendan Smith (TD Cowen)

2026Q2: I know we’ll get confirmation of the first two assets by early next year. Just wondering if you can give us a little bit more of a sense of timing for subsequent assets in that pipeline... is that more of a 2028 event? - Brendan Smith(TD Cowan)

Contradiction Point 2

Assumed Asset Count for $1 Billion HyperCon Royalty Target

Inconsistent guidance on the number of launches needed to hit the $1B royalty milestone.

Brendan Smith (TD Cowan) - Brendan Smith (TD Cowan)

2026Q2: The $1 billion projection in the mid-2030s assumes 5-7 launches, which could come from both existing and potential new agreements over the next 1-2 years. - Dr. Helen Torley(CEO)

What is the timing for subsequent HyperCon assets beyond the first two, and how many assets are assumed in the $1 billion incremental royalty target by 2035, based on current or future partnerships? - Brendan Smith (TD Cowen)

2026Q2: I guess, how many different assets are you assuming would contribute to that by 2035? I guess, are your assumptions largely just based on current partnerships, or are you assuming any additional ones? - Brendan Smith(TD Cowan)

Contradiction Point 3

HyperCon Manufacturing Scale-Up and Investment Timeline

Contradiction on when manufacturing investment details will be finalized.

Mitchell Kapoor (HC Wainwright) - Mitchell Kapoor (HC Wainwright)

2026Q2: Investing in manufacturing is key... Specific investment details are not yet finalized, but it is intended to drive the platform to its $1 billion+ potential more quickly than Enhance. - Dr. Helen Torley(CEO)

How should we think about potential revenue beyond royalties and incremental investment impacts on 2026-2028 margins, as well as attrition risks in the 13 enhanced programs leading to 2029 launches? - Brendan Smith (TD Cowen)

2026Q1: Halozyme is currently working on clinical manufacturing and investing in end-to-end manufacturing capacity to enable these first-half 2027 phase I starts. - Dr. Helen Torley(CEO)

Contradiction Point 4

Launch Window for the 13 Development Programs

Contradiction on the range of years for the earliest possible launches of the 13 programs.

Mitchell Kapoor (HC Wainwright) - Mitchell Kapoor (HC Wainwright)

2026Q2: Launches will occur between 2029-2033, not all in 2029, with development timelines of 4-5 years. - Dr. Helen Torley(CEO)

How should we think about potential revenue beyond royalties and incremental investments in 2026-2028 margins, and what is the potential attrition impact on the 13 enhanced programs leading to 2029 launches? - Brendan Smith (TD Cowen)

2026Q1: The earliest launches could begin in 2029, with the latest occurring around 2031-2032. - Dr. Helen Torley(CEO)

Contradiction Point 5

HyperCon Clinical Timeline and Product Launch Assumptions

Timeline for clinical starts and program launches appears accelerated between Q4 2025 and Q2 2026.

Brendan Smith (TD Cowan) - Brendan Smith (TD Cowan)

2026Q2: Additional HyperCon study starts could occur in the second half of 2027, as partners advance multiple targets. - Dr. Helen Torley(CEO)

What is the timing for subsequent HyperCon assets beyond the first two, and how many assets are assumed for the $1 billion incremental royalty target by 2035, based on current or future partnerships? - Corinne Jenkins (Goldman Sachs)

20260218-2025 Q4: Halozyme is supporting two partners to advance two Hypercon programs to Phase I clinical testing in 2026. The steps include completion of clinical scale-up batches and IND package filings. Everything is on track for clinical starts by the end of 2026. - Helen Torley(CEO)

<<>>